TITLE

Diagnosis and treatment of Paget's disease of bone

AUTHOR(S)
Josse, Robert G.; Hanley, David A.; Kendler, David; Ste Marie, Louis-Georges; Adachi, Jonathan D.; Brown, Jacques
PUB. DATE
October 2007
SOURCE
Clinical & Investigative Medicine;Oct2007, Vol. 30 Issue 5, pE210
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Paget's disease of bone (PDB) is a metabolic bone disease characterized by increased bone resorption followed by excessive unregulated bone formation. This results in weakened, deformed bones of increased mass in which the collagen fibres assume a haphazard irregular mosaic pattern instead of the normal parallel symmetry. PDB rarely occurs before middle age and its prevalence increases steadily with age. The overall prevalence in Caucasians is approximately 3%; although it appears to be declining. There is a geographic variation in prevalence, with highest rates found in the UK. PDB affects both men and women, with a slight predominance in men. PDB may be asymptomatic or symptomatic, depending on the bones involved; the??most common symptom is pain in the affected bone. While its aetiology remains elusive, genetic factors and environmental influences are implicated. In 2002, guidelines for PDB management were developed in Great Britain and have gained worldwide acceptance. In this position paper, an Expert Panel of Canadian endocrinologists and rheumatologists examines current evidence on the diagnosis and treatment of PDB to provide Canadian recommendations. In general, diagnosis may be confirmed both by X-ray and by the biochemical marker serum alkaline phosphatase, which is elevated in 85% of individuals with untreated active PDB. Treatment is indicated for all patients with symptoms and for asymptomatic patients with active PDB in areas of the skeleton with the potential to produce complications of clinical importance. The Panel recommends treating PDB with bisphosphonates that have demonstrated superior efficacy and remission rates.
ACCESSION #
27130120

 

Related Articles

  • Diagnosis and Treatment of Paget's Disease of Bone. Schneider, Doron; Hoffman, Mary T.; Peterson, Jeanette A. // American Family Physician;5/15/2002, Vol. 65 Issue 10, p2069 

    Paget's disease of bone (also known as osteitis deformans) is a nonmalignant disease involving accelerated bone resorption followed by deposition of dense, chaotic, and ineffectively mineralized bone matrix. The origin of the disease is unknown, and it is frequently asymptomatic; however, the...

  • Paget disease of bone: A classic case report. SHANKAR, Y. UDAY; MISRA, SATYA RANJAN; VINEET, DANIEL ALEX; BASKARAN, PAVITRA // Contemporary Clinical Dentistry;Apr-Jun2013, Vol. 4 Issue 2, p227 

    Paget disease of bone (PDB) is a chronic progressive disease of the bone of uncertain etiology, characterized initially by an increase in bone resorption, followed by a disorganized and excessive formation of bone, leading to pain, fractures, and deformities. It can manifest as a monostotic or...

  • Elevated alkaline phosphatase: a diagnostic pearl for Paget's disease. Sanyal, K.; Sabanathan, K. // British Journal of Hospital Medicine (17508460);Mar2008, Vol. 69 Issue 3, p169 

    The article reports on the case of a 96-year old man presented with dizziness, falls, gradual onset of deafness and generalized joint pain. On his examination, all the blood tests were unremarkable except his alkaline phosphatase level. Meanwhile, a skull X-ray showed typical mosaic pattern of...

  • Pathogenesis, diagnosis and management of Paget's disease of the bone. Walker, Jennie // Nursing Older People;Oct2014, Vol. 26 Issue 8, p32 

    Paget’s disease of the bone is a chronic condition that affects bone remodelling in focal areas of the skeleton. The disease may affect one or several sites and can cause a variety of subsequent complications such as pain, bony deformity, osteoarthritis, fracture or nerve compression....

  • Bisphosphonates inhibit bone resorption. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;07/25/97, Vol. 10 Issue 7, p19 

    States that bisphosphonates, synthetic analogues of pyrophosphate slow bone resorption by inhibiting the action of osteoclasts in Paget's disease. Alendronate therapy for women; Pamidronate therapy.

  • Paget's Disease of Bone. Roodman, David // Current Medical Literature: Rheumatology;2006, Vol. 25 Issue 4, p89 

    The article provides information on Paget's disease of the bone. Both genetic and environmental factors appear to contribute to the etiology of the disease. Patients with this disease are often diagnosed with a combination of biochemical markers of bone turnover and radiological abnormalities....

  • Paget’s disease: a clinical review. Shah, Mukul; Shahid, Farhan; Chakravarty, Kuntal // British Journal of Hospital Medicine (17508460);Jan2015, Vol. 76 Issue 1, p25 

    The article discusses the basic science and clinical aspect of Paget's disease of the bone. Topics discussed include the use of biochemical screening for the diagnosis of disease, its associations with bone and neoplastic lesions, national guidelines in Great Britain for the treatment of the...

  • Paget's disease of pelvis mimicking metastasis in a patient with lung cancer evaluated using staging and follow-up imaging with fluorine-18 fluorodeoxyglucose-positron emission tomography/ computed tomography. Kamaleshwaran, Koramadai Karuppusamy; Natarajan, Sudhakar; Shibu, Deepu; Malaikkal, Anjali; Shinto, Ajit Sugunan // Indian Journal of Nuclear Medicine;Apr-Jun2015, Vol. 30 Issue 2, p151 

    Paget's disease of bone is a benign disease, of uncertain etiology, characterized by an accelerated turnover, that is, bone resorption and formation. Paget's disease may be present in up to 5% of the population, and the majority of cases are asymptomatic. We report the imaging findings of...

  • Recombinant Osteoprotegerin for Juvenile Paget's Disease. Cundy, Tim; Davidson, James; Rutland, Michael D.; Stewart, Carolyn; DePaoli, Alex M. // New England Journal of Medicine;9/1/2005, Vol. 353 Issue 9, p918 

    Juvenile Paget's disease, a genetic bone disease characterized by accelerated bone turnover, results from inactivating mutations in the gene encoding osteoprotegerin — a key regulator of osteoclastogenesis. The effects of recombinant osteoprotegerin were investigated in two adult siblings...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics